China drug stock surges after doctor endorses its treatment for Covid
Guangzhou
A MAKER of traditional Chinese medicine products saw its stock surge the most in two years on Friday after one of the nation's top medical advisers reportedly said one of its treatments could potentially inhibit Covid-19.
Speculative traders pushed Guangzhou Baiyunshan Pharmaceutical Holdings up 13 per cent in Hong Kong and by its 10 per cent limit in Shanghai. Guangzhou-based Nanfang Daily cited Zhong Nanshan as saying Baiyunshan's "banlangen" product was effective in a series of in-vitro studies. Mr Zhong is a senior medical adviser to Beijing who confirmed the risk of human-to-human Covid-19 infection on Jan 20.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
UBS weighs synthetic risk transfer amid capital boost proposals
Oil settles higher on supply concerns in the Mid-East, economic woes subdue gains
S-Reits falter as investors weigh possibility of zero rate cuts in 2024
CapitaLand Investment posts total revenue of S$650 million for Q1
Europe: Stoxx 600 logs best day in three months as banks shine
US: Stocks rally after strong tech results